Prostate cancer (PrCa) is characterized by progression from an androgen-dependent phenotype to one that is inevitably androgen independent (AI) and lethal. Recent evidence strongly suggests that the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) and androgen receptor (AR) signalling pathways provide prostatic epithelium with the necessary signalling events to escape the apoptotic response associated with androgen withdrawal therapy. Silencing of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and glycogen synthase kinase b (GSK3b) are frequently associated with advanced PrCa systems and likely serve critical roles in promoting AR and PI3K/Akt gain-of-function. That PTEN negatively regulates AR and is sufficient to promote metastatic PrCa in murine models strongly implies its role as a gatekeeper of progressive PrCa. In human PrCa, PTEN loss is correlated with substantial increases in Akt Ser473 and integrin-linked kinase expression, both of which promote Ser 9 phospho-inhibition of GSK3b and inactivation of apoptotic factors. Sufficient evidence also suggests that GSK3b is not only a critical regulator of proproliferative signalling but also a promiscuous one as PI3K/Akt pools of GSK3b are, at least in part, functionally interchangeable with those of the Wnt/b-catenin pathway. Thus, GSK3b may serve not only as a mediator of PI3K/Akt activation but may also regulate the potent transactivation and proproliferative effects that Wnt3a and b-catenin confer upon AR. These data suggest that prostate-specific activation of GSK3b may serve as a viable pharmacological option. Thus, in this review, we emphasize that temporal changes in GSK3b and PTEN expression during progression to AI PrCa are important factors when considering the potential for therapies targeting the oncogenic contributions of PI3K/Akt and AR signalling pathways.
Prostate cancer (PrCa) is characterized by progression from an androgen-dependent phenotype to one that is inevitably androgen independent (AI) and lethal. Recent evidence strongly suggests that the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) and androgen receptor (AR) signalling pathways provide prostatic epithelium with the necessary signalling events to escape the apoptotic response associated with androgen withdrawal therapy. Silencing of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and glycogen synthase kinase b (GSK3b) are frequently associated with advanced PrCa systems and likely serve critical roles in promoting AR and PI3K/Akt gain-of-function. That PTEN negatively regulates AR and is sufficient to promote metastatic PrCa in murine models strongly implies its role as a gatekeeper of progressive PrCa. In human PrCa, PTEN loss is correlated with substantial increases in Akt Ser473 and integrin-linked kinase expression, both of which promote Ser 9 phospho-inhibition of GSK3b and inactivation of apoptotic factors. Sufficient evidence also suggests that GSK3b is not only a critical regulator of proproliferative signalling but also a promiscuous one as PI3K/Akt pools of GSK3b are, at least in part, functionally interchangeIntroduction Prostate cancer (PrCa) is one of the most frequently diagnosed cancers and a leading cause of male mortality (McDavid et al., 2004) . Although androgen blockade therapy is initially successful, the inevitable evolution of PrCa from an androgen-dependent (AD) to androgenindependent (AI) phenotype allows for continued cell proliferation and production of prostate-specific antigen (PSA). PSA serves not only as one of the few, direct gene targets of AR but also as a sensitive marker for progressiveness of PrCa and effectiveness of treatments (Kim and Coetzee, 2004) . Acquisition of AI PrCa and elevated serum PSA coincides with enhanced autocrine growth factor function, increased dependency upon phosphatidylinositol-3-kinase/Akt (PI3K/Akt) signalling and more promiscuous androgen receptor (AR) activity.
Loss of tumour suppressor function is a frequent genetic event occurring during progressive PrCa and is associated with gain-of-function, oncogenic signalling (Isaacs and Kainu, 2001 ). Thus, loss of tumour suppressor function is likely associated with the required 'switches' for the development of a progressive cancerous phenotype. Those suppressors that have been well documented to undergo loss of function during progressive PrCa include the retinoblastoma protein (Bookstein et al., 1990; Phillips et al., 1994) , NKX3.1 (He et al., 1997; Bowen et al., 2000; Asatiani et al., 2005) , p53 (Massenkeil et al., 1994; Thompson et al., 1995) and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) (Davies et al., 1999; McMenamin et al., 1999) . However, with the increasing understanding that PI3K/Akt and AR undergo gain-of-function roles to promote the lethal, phenotype of androgen independence, considerable documentation has arisen to those suppressors regulating these pathways and their crossregulation. PTEN (Steck et al., 1997; Stiles et al., 2004) and glycogen synthase kinase b (GSK3b) (Doble and Woodgett, 2003) both have potent tumour suppressor qualities, thereby regulating cell proliferation, apoptosis and growth. While PI3K/Akt cell signalling can elicit cellular responses through an array of effector pathways including cell cycle (GSK3b), cell death (Mdm2), protein synthesis (mTOR), cell growth (p70 S6 kinase) and cell survival (BAD, JNK) (Downward, 2004) , those occurring via receptor tyrosine kinases/Akt/GSK3b route have precipitated considerable interest and documentation with respect to AR and PI3K function during AI PrCa.
The opposing functions of AR and PI3K/Akt oncogenic signalling and the tumour suppressor functions of PTEN and GSK3b provide an enticing platform by which to assess how changes in key cell signalling events permit cancerous prostatic epithelium to undergo continued cell proliferation during hormone blockade therapy. Having put forth these key players, we will consider several critical issues that are outstanding within the current literature: (1) What is the evidence that PI3K/ Akt and AR signalling serve critical roles in cell survival and proliferation during progression to AI PrCa? (2) What are the means by which loss of PTEN promotes a signalling environment that is highly PI3K/Akt and AR dependent? (3) How does GSK3b serve as a critical mediator of proproliferative signalling elicited by upstream PI3K and Wnt prosurvival stimuli? (4) How might PrCa cells accommodate increased PI3K/Akt signalling in cells expressing PTEN? The intensity of studies relating these events to continued cell proliferation during AI PrCa is testament to their importance. While review and analysis of such literature reveals many consistent themes, it is also apparent that many observations are system and context dependent and, thus, require caution when extrapolating to in vivo settings.
PI3K/Akt and AR: critical regulators of progression to AI PrCa
Several lines of evidence suggest that PI3K/Akt signalling serves a critical, compensatory role in allowing systems of prostatic carcinoma to maintain continued proliferation in low androgen environments. Loss of PTEN expression, whether by loss of heterozygosity or mutational silencing, results in accumulation of the phospholipid, phosphoinositol-(3,4,5)-triphosphate (PIP 3 ), and a resulting phosphorylation of Akt at the submembranous position (Hemmings, 1997) . As such, PrCr cell lines that have been obtained from metastatic lesions (e.g. LNCaP, PC3) or that are strictly AI (e.g. 22RV-1, C4-2) harbour highly active PI3K/Akt signalling (Davies et al., 1999; Murillo et al., 2001; Gao et al., 2003) . Phosphorylated Akt is also highly expressed in PrCas with high Gleason grade (Malik et al., 2002) and is an excellent predictor of clinical PSA failure (Kreisberg et al., 2004) . Chemical inhibitors targeting the catalytic unit of PI3K, such as LY294002 and Wortmanin, induce a potent apoptotic response in most PrCa cell lines including LNCaP, LAPC4 and LAPC9 (Lin et al., 1999) . Rapamycin or CCI-779 targeting of mTOR, a main PI3K/Akt growth effector, can promote cell cycle arrest of PrCa cell lines, xenografts (Wu et al., 2005) and reversion of prostatic intraepithelial neoplasia (PIN) phenotype (Majumder et al., 2004) ; small molecule inhibition of Akt 1 and 2 isoforms have also proven effective inducers of caspase-3 (DeFeo-Jones et al., 2005) . However, inhibitors targeting MAPK (e.g. PD98059) and Ras signalling pathways do not elicit these types of responses (Lin et al., 1999) .
Despite that overexpressed Akt promotes substantial increases in LNCaP PrCa xenograft growth (Graff et al., 2000) , the MPAkt transgenic mouse (Majumder et al., 2003) clearly demonstrates the capacity to form PIN, but not invasiveness. These data affirm that Akt function may be required but insufficient for development of PrCa. Nonetheless, these results collectively demonstrate the significance of upstream PI3K/Akt signalling activity in providing critical signals for progressive PrCa.
Compelling evidence also implicates AR as serving an oncogenic role during progression to AI PrCa. Gene amplification (Koivisto et al., 1997) , gain-of-function mutations (Ratliff, 2005) , increased protein expression (Chen et al., 2004a) and sensitivity to low levels of androgens (Mohler et al., 2004) have been documented as means by which AR may accommodate survival in low androgen environments during hormone refractory PrCa. Using PrCa xenografts, it has been demonstrated that AR is bound to the PSA promoter enhancer during AD and recurrent PrCa, but not during initial androgen withdrawal . This suggests that AR may acquire increased association with chromatin, therefore, enhancing gene activation during AI PrCa. Further, the pure antagonist of AR, bicalutamide, invokes decreased mitotic activity and growth in PrCa cell lines (Lin et al., 1999) and has been reported to induce an apoptotic response in rat ventral prostate (Nickerson and Pollak, 1999) . Finally, studies facilitating hammerhead ribozyme (Zegarra-Moro et al., 2002) or RNAi knockdown of AR (Chen et al., 2004a) indicate that AR may be necessary for proliferation in AI cell lines and xenograft models, respectively. Thus, androgen ablation, blockade or direct inhibition of AR appears to provide a distinct reduction in growth advantage for PrCa systems.
Increased association of AR with transcriptional coregulators is also a major hypothesis governing AR gain-of-function in low androgen environments. Coregulators that are well documented to be potent activators of AR with the potential to alter ligand specificity of AR include CBP (Comuzzi et al., 2003) , SRC (Nazareth et al., 1999) , TIF-2 (Gregory et al., 2001) and those specific to AR including ARA54 (Kang et al., 1999) and ARA70 (Yeh and Chang, 1996) . However, if PI3K/Akt and AR activation are functionally important during AI PrCa, then those coactivators that are subject to crossregulation by either pathway may be of greater significance than previously recognized.
One coregulator of increasing documentation is b-catenin, a well-known oncoprotein and potent transcriptional coactivator of AR (Truica et al., 2000; Mulholland et al., 2002 Mulholland et al., , 2003 Song et al., 2003b; Chen et al., 2004b) . b-Catenin can enhance cell proliferation (Mulholland et al., 2003; Masiello et al., 2004) , production of PSA and increase AR responsiveness to nonandrogen ligands, including estrogens (Truica et al., 2000; Pawlowski et al., 2002; Song et al., 2003b; Mulholland et al., 2003; . Mice with prostate-specific deletion of the b-catenin regulatory domain (Dexon 3) are reported to develop metaplasia and, in some instances, neoplastic transformation (Bierie et al., 2003; Gounari et al., 2002) . Importantly, increased b-catenin expression has been correlated with apoptotic-resistant PrCa (De La Taille et al., 2003) and is markedly increased in high-grade PrCa (Chen et al., 2004b) . That b-catenin is regulated by a diversity of prosurvival pathways, including PI3K/Akt and Wnt, presents b-catenin as an interesting collaborator to AR during transition from AD to AI PrCa.
Loss of PTEN provides a gain-of-function 'environment' for AR
The conditional PTENÀ/À mouse model develops all stages of progressive PrCr including invasion, metastasis and androgen independent proliferation (Wang et al., 2003) . That biallelic deletion of PTEN is sufficient to promote metastatic PrCa strongly suggests the status of PTEN expression as a critical switch in preventing or permitting enhanced cell proliferation during AI PrCa. Even though PTEN loss serves to promote heightened PI3K/Akt activity and metastasis, prostatic epithelium from PTENÀ/À mice are still sensitive to androgen withdrawal (Wang et al., 2003) . Furthermore, while androgen ablation causes prostate regression, the rate of epithelial proliferation appears to remain constant (Wang et al., 2003) . Thus, a likely presumption is that while AR remains functional and sensitive to androgens, PI3K/Akt and AR oncogenic signalling may also complement and compensate for one another to promote continued cell proliferation during the cellular stress of androgen ablation. This hypothesis is strongly supported by the observation that cells, grown both in vitro and in vivo, lacking PTEN display elevated activity of the PI3K/Akt axis upon acute androgen withdrawal, as assayed by phospho-Akt Ser473 levels (Murillo et al., 2001; Wang et al., 2003) . It also underscores the presumption that, subsequent to androgen ablation, PTEN loss may allow surviving epithelium with sufficient PI3K/Akt signalling to maintain continued cell proliferation and provoke AR gain-of-function.
Amplification of AR occurs in most PrCa xenografts (Chen et al., 2004a) , in the PTENÀ/À conditional mouse model (H Wu, lab unpublished observations), in the Myc transgenic mouse model (Ellwood-Yen et al., 2003) and in advanced human PrCa (Chen et al., 2004a) . If this is true, then a reasonable speculation is that PTEN loss may be correlated with increased AR stabilization and association with active transcriptional complexes. The use of PrCa mouse models will likely provide important clues as to whether in vivo loss of PTEN is a direct causal agent for promoting AR-specific gene activation. However, until such mouse genetics are accurately carried out, important observations gained by in vitro studies will continue to define the relationship between PTEN and AR. In vitro observations by Li et al. (2001) suggest an antagonistic relationship, as PTEN can negatively regulate AR gene targets including expression of PSA (Li et al., 2001) . Forced expression of PTEN can also reduce nuclear localization of AR and promote receptor degradation by way of caspase-3 or the proteosome system (Lin et al., 2004) . As a caveat, such studies have indicated that expression of PTEN, in the presence of androgens, is sufficient to reduce cell proliferation but not to induce an apoptotic response (Li et al., 2001; Nan et al., 2003; Lin et al., 2004) . These data imply the presence of AR-regulated 'survival' genes that may function independently of PI3K/Akt signalling. Identification and therapeutic targeting of such genes could prove effective in sensitizing tumours to inhibitors, such as rapamycin, which target the PI3K/ Akt pathway (Sharp and Bartke, 2005) .
Exogenous PTEN expression, in PTEN null backgrounds, can also negate coregulators of AR. For example, PTEN regulates, by way of altered GSK3b function, the localization of b-catenin, its transcriptional effector, T-cell factor (Tcf) (Persad et al., 2001b; Sharma et al., 2002) and its target cell cycle regulator, cyclin D1 (Radu et al., 2003) . Loss of PTEN may, therefore, result in increased nuclear localization of AR/b-catenin complexes (Mulholland et al., 2002; Pawlowski et al., 2002) , potentially leading to alteration of cell cycle events or ligand specificity of AR. A logical extrapolation is that PTEN loss may promote AR gain-of-function by modulating other known AR coregulators including ARA70 (Yeh and Chang, 1996) and ARA54 (Kang et al., 1999) , thereby permitting responsiveness to low androgen levels or nonandrogen ligands. As changes in phosphorylation, sumoylation and ubiquitylation have all been associated with altered nuclear receptor function (Fu et al., 2003a (Fu et al., , b, 2004 , a reasonable conjecture is that loss of PTEN expression could also promote gain-of-function AR post-translational modifications (PTMs). For example, phosphorylation (Wong et al., 2004) and acteyltransferase modification of AR by cofactors, including CBP/p300, P/CAF and TIF-2, are associated with ligand-independent activation of AR. CBP/p300, a known coactivator both of AR (Comuzzi et al., 2003) and b-catenin (Takemaru and Moon, 2000) , can govern the manner by which AR responds to ligands with either agonist or antagonist qualities. Such studies could be efficiently tested using mouse models that demonstrate all stages of progressive PrCa, such as the PTENÀ/À model (Wang et al., 2003) combined with mass spectrometry analysis of AR enrichments.
Thus, PTEN loss-of-function may result in AR gain-of-function by at least four means: (1) reduced employment as a caspase-3 or proteosome substrate; (2) activation by PTMs; (3) increased gene activation promoted by the Wnt/b-catenin axis and other potent coactivators, and (4) decreased corepressor activities. Collectively, the current literature best argues that PTEN loss may coincide with increased AR oncogenicity, development of hormone refractory PrCa and/or metastatic potential. However, whether PTEN loss is required for acquisition of a 'super AR', in vivo remains to be determined.
GSK3b: an Akt-dependent tumour suppressor kinase that regulates AR GSK3b and its upstream regulator, Akt, engage in a complex interplay of phosphoregulation and have both been documented as direct regulators of AR function. While it is clear that Akt negatively regulates GSK3b activity by Ser 9 phosphorylation, it is less understood how the balance between Akt and GSK3b may dictate the net outcome of AR activity. Thus, while functional interactions between Akt, GSK3b and AR are of apparent confusion, these data are more easily understood when cell lines of study, the state of PI3K/Akt activation and the experimental concentration of androgens are considered.
Several lines of evidence suggest that GSK3b functions as a critical regulator of mechanisms leading to AI PrCa including regulation of AR oncogenic function. GSK3b-dependent phosphorylation of the AR hinge and ligand binding regions results in decreased activation of AR gene targets and also promotes inhibition of cell proliferation (Salas et al., 2004; Wang et al., 2004) . Reports that pharmacological inhibition (LY294002) of PI3K/Akt promotes a net increase in AR phosphorylation (Salas et al., 2004) suggest that GSKb, and possibly other kinases, may promote greater phosphorylation of AR in cells with basal PI3K/Akt activity (as opposed to those with constitutive signalling Akt function) observed during advanced PrCa. However, given the reported repressive effects that GSK3b confers upon AR, it is paradoxical that GSK3b has also been shown to be required for AR gene expression (Liao et al., 2004) . A plausible interpretation of this observation is that, while basal activity of GSK3b is required for AR function, any increases may result in decreased AR function either directly, through phosphorylation, or indirectly, through inhibition of effectors such as b-catenin.
Akt, one of the few known regulators of GSK3b, has a complex relationship with AR. By in vitro kinase assays, Akt has been demonstrated to preferentially phosphorylate hAR at Ser 210 and Ser
790
, as compared to AR with Ser-Ala phosphorylation site mutations (Lin et al., 2001 (Lin et al., , 2003 . Akt phosphorylation of AR has been reported to yield both activation (Wen et al., 2000) and inhibition of AR transactivation (Lin et al., 2001 (Lin et al., , 2003 . Additional controversy arises from mass spectrometry analysis of AR enrichments from LNCaP PrCa cells, which failed to detect putative Akt phosphorylation sites (Gioeli et al., 2002) . In fact, mutational alteration of Akt phosphorylation sites show little effect upon AR transcription (Gioeli et al., 2002) . Conflicting information regarding the direct post-translation modification that Akt confers upon AR (either directly or via GSK3b) could be attributed to use of varying androgen concentrations, systems of study or passage of cell lines. Studies documenting Akt-mediated phosphorylation and repression of AR occurred at higher concentrations of DHT (Lin et al., 2001 (Lin et al., , 2003 . However, it is well documented by in vitro studies that AR gene activation and cell viability are also dependent upon the local concentration of androgens. For example, studies suggest that at low androgen concentrations (o1 nM DHT) LNCaP cell viability is greater than at higher androgen concentrations (>10 nM DHT). While gene activation is greater at higher concentrations of androgens, AR gene targets also include those with apoptotic potential (Yuan et al., 1993; Heisler et al., 1997) , such as the cell cycle inhibitor, p21 (Lu et al., 2000) . If, in presence of growth factor activation of the PI3K cascade, Akt attenuates AR gene expression, then a resulting decrease in p21-mediated apoptosis may occur. The net effect would be one of enhanced cell proliferative/apoptotic index (Lin et al., 2001 (Lin et al., , 2004 , and suggests that while Akt may directly negate AR gene activation, the overall effect may be one of synergism. Thus, while it is possible that the concentration of androgens dictates whether AR serves as a phosphosubstrate for Akt, perhaps the more important read-out is whether there is synergy between AR and Akt with respect to cell viability. Interestingly, other studies have rationalized differential interactions between AR and Akt to be a function of cell line passage with LNCaP PrCa cells displaying increased reliance upon PI3K/Akt signalling with increasing passage number (Lin et al., 2003) . Increasing evidence suggests that AR and PI3K/ Akt are autoregulatory and, thus, could be subject to positive or negative feedback mechanism. This has been recently demonstrated in LNCaP PrCa cells in which mTOR, a positive effector of PI3K/Akt (Sarbassov et al., 2005) , can serve to negatively regulate AR by PTM (Cinar et al., 2005) . In some respects, these observations are difficult to reconcile, given that both AR and PI3K/Akt are thought to acquire gain-offunction signalling mechanisms during AI PrCa. However, it is possible that short-term in vitro observations and long-term in vivo observations are considerably different. Short-term activation of PI3K/Akt may reveal that the net outcome of Akt/AR interactions likely fluctuates between activation and inhibition by way of positive and negative PTM. This could possibly be elicited by shifts between Akt-, GSK3b-and mTORdependent phosphorylation of AR.
While short-term, in vitro assays (e.g. transfectionbased luciferase assays) may provide one measure of AR response, they may not reflect long-term, steady-state regulation that is clinically relevant during prolonged hormone ablation therapy and hormone refractory PrCa. During chronic androgen ablation, PTEN loss likely elicits increased levels of phosphorylated Akt, decreased GSK3b function and AR gain-of-function. Although a strong argument can be made for progressive synergism of AR by Akt, and potentially other kinases, the significance of total changes in AR phosphorylation during progression to AI PrCa remains to be determined. Analysis of cytoplasmic versus nuclear pools of phosphorylated AR may decipher whether ligand activation or cellular localization alter AR phosphorylation and whether this PTM is functionally important. Importantly, recent studies facilitating a prostate renal graft regeneration system (Xin et al., 2003) will likely fill a void in our understanding of AR/ Akt interactions in prostatic epithelium. Prostatic epithelium reconstituted in a cis manner, with both AR and Akt, clearly demonstrate synergism in cell proliferation. However, grafts consisting of overexpressed AR and Akt functioning in trans do not display this phenotype. These data strongly suggest that the net outcome of AR and Akt signalling events result in oncogenic gain-of-function rather than one of repression (L Xin and ON Witte, personal communication; David Geffen School of Medicine, UCLA). However, whether Akt phosphorylation of AR occurs during AI PrCa and whether this PTM is functionally relevant to an AI phenotype, in vivo, remains to be determined. Certainly, in vivo regeneration studies reconstituting prostatic epithelium (in cis) with constitutively active Akt and AR forms lacking Akt phosphorylation sites could provide an answer to this critical question. Ultimately, mouse genetic experiments will need to be carried out targeting functional domains of Akt including the PH or kinase regions. Crossing of Akt conditional knockout lines with well-established mouse PrCa models, including the PTENÀ/À mouse model (Wang et al., 2003) or the TRAMP model (Gingrich et al., 1999) , will provide greater insight as to the role for Akt, and therefore GSK3b.
PTEN and GSK3b are key dictators of Wnt/PI3K crossregulation
GSK3b is a critical, negative regulator both of PI3K and Wnt cell signalling (Ding et al., 2000) . The ability of GSK3b to phosphorylate the regulatory domain of b-catenin in addition to PI3K/Akt-dependent cell cycle regulators suggests an important role in regulating cell proliferation during progressive PrCa. While it has been argued that the GSK3 pools associated with Wnt and PI3K/Akt pathways are different (Ding et al., 2000) , it has become increasingly apparent that PI3K and Wnt/bcat can crossregulate via GSK3b pools as elicited by upstream activators such canonical Wnts and IGFs. Autocrine production of IGF-1 and increased IGF1-R levels are both correlated with progressive PrCa and systems harbouring enhanced activity of the PI3K/Akt axis (Nickerson et al., 2001; Krueckl et al., 2004) . Complexing of IGF-1 with the IGF-1R enhances AR transactivation and endogenous PSA production (Culig et al., 1994) . Thus, an attractive hypothesis is that IGF-1 enhancement of growth and proliferation may occur as a result of stabilization, nuclear localization of b-catenin and enhanced b-catenin/AR interactions . These observations are consistent with the finding that IGF-1R increases substantially in AI PrCa systems (Krueckl et al., 2004) and that PTEN also regulate levels of IGF-1R (Zhao et al., 2004) . Use of monoclonal antibodies, interfering RNAs, antisense oligonucleotides or small molecule inhibitors (e.g. NVP-ADW742) (Warshamana-Greene et al., 2004) designed to block IGF-R function could, therefore, serve to block indirectly the proliferative promoting effects of b-catenin. This suggests that the synergy between AR and Akt can be enhanced not only through IGF-1 activation but also by the coactivating effects of b-catenin.
Wnt3a, a ligand for canonical Wnt signalling, has the capacity both to promote nuclear translocation of b-catenin and to promote ligand-independent activation of AR . Interestingly, while Wnt3a enhances AR function , Wnt11, a noncanonical Wnt, antagonizes AR in AD LNCaP PrCa cell lines but not in the LNCaP-r hormone refractory cell line (Zhu et al., 2004) . Thus, loss of the Wnt11-mediated inhibition of AR in AI PrCa cells may provide an additional means for AR oncogenic function. Other canonical Wnts may also serve to activate the cytoplasmic regulator, Dishevelled, to disengage GSK3b/Axin complexes, thereby promoting b-catenin accumulation and activation of AR. Recent advances in the production of active, recombinant Wnts (Willert et al., 2003) will be important in determining how other canonical and noncanonical Wnts alter AR function. While the role of b-catenin in PrCa as an initiator of oncogenesis or contributor of cell proliferation, or both, remains to be deciphered, these data raise two important points: (1) In PTEN null environments, IGF-1 and Wnts can readily enhance AR function by way of b-catenin recruitment. This suggests that other extracellular activators capable of ligand-independent activation of AR, including EGF, IL-6 and KGF (Culig et al., 1994) , may also promote AR ligand promiscuity via b-catenin or other coregulators. (2) It affirms that PI3K/Akt and Wnt/b-catenin-associated pools of GSK3b are not mutually exclusive but, rather, may interact to mediate upstream growth factor activators (Figure 1 ).
Enhanced GSK3b activity: a good thing in AI PrCa?
While many pathologies may benefit from use of GSK3b inhibitors (Meijer et al., 2004) , AI PrCa cells would likely be more susceptible to pharmacological activation of GSK3b, either by direct or indirect means. Although the obvious challenge is targeted delivery, development of GSK3b activators that can be administered locally to the prostate may be beneficial in reducing proliferative cell signalling. For example, peptidomimetics (Perez et al., 2002) may be used to block GSK3b/14-3-3 protein interactions, thereby leaving GSK3b functionally active. Increasing the kinase activity of GSK3b pools could serve not only to abrogate b-catenin function, and AR gene targets, but also to inhibit the growth promoting effects that result from PI3K/Akt stimulating of S6K and mTOR (Vivanco and Sawyers, 2002) . This strategy may also serve to abrogate Wnt signalling by promoting direct inhibition of the cell cycle regulators, cyclin D1 and p21 CIP (van Es et al., 2003) . As AR can directly inhibit PI3K effectors of cell death, including forkhead family members (FKHR, FOXO) (Li et al., 2003; Huang et al., 2004) and NF-kB (Altuwaijri et al., 2004) , pharmacological activation of GSK3b-, PI3K-and Wnt-sensitive systems could promote sensitization to apoptosis and delay progression to AI PrCa. GSK3b activation may not only prevent accumulation of b-catenin but may also result in degradation of target substrates including c-jun, cyclin D1 and c-myc (Anna et al., 2003; Bernard et al., 2003; Ellwood-Yen et al., 2003) . That prostate-specific overexpression of c-myc results in prostatic neoplasia (Zhang et al., 2000; Ellwood-Yen et al., 2003) further underscores the potential for therapeutic activation of GSK3b, a negative regulator of c-myc.
Integrin-linked kinase (ILK) has also been demonstrated to directly phosphorylate Akt Ser473 sites, thereby indirectly repressing GSK3b (Persad et al., 2000 (Persad et al., , 2001a Hannigan et al., 2005) . ILK expression also increases during progressive PrCa (Graff et al., 2001; Qi et al., 2005) , thus validating it as a potential target. Clearly, the by-product of heightened PI3K/Akt and ILK activity in AI PrCa is concomitant with Ser 9 phosphoinhibition of GSK3b pools (Persad et al., 2000 (Persad et al., , 2001a and relatively little antagonism to b-catenin accumulation. More recent data suggest that ILK activity may regulate acute Wnt signalling and b-catenin stabilization, independent of GSK3b (S Dedhar, personal communication, BC Cancer Agency). Thus, with the capacity to phosphoactivate Akt and to phosphoinactivate GSK3b, ILK may serve as a critical mediator of proliferation in PrCa. Therapeutic targeting of ILK (Tan et al., 2004) may prove to have a dual effectiveness by indirectly, inhibiting Akt synergy with AR and enhancing the inhibitory effects that GSK3b has on b-catenin function. Potential pitfalls of systemic delivery of GSK3b activators would be the obvious effects upon glucose metabolism, thus underscoring the preference for targeted delivery of GSK3b activators or ILK inhibitors to the prostatic epithelium. However, for the time being, upstream molecules responsible for activation of GSK3b remain elusive and, thus, their identification will remain critical in the development of therapeutic regulators for advanced PrCa.
PTEN: not the final verdict
Levels of PIP 3 are clearly critical in regulating the effects of Akt, GSK3b and b-catenin. However, as PrCa is a heterogeneous and multifocal disease, PTEN loss is not an exclusive event (Dreher et al., 2004; Koksal et al., 2004) . Through immunohistochemical analysis of human PrCas, a significant portion (>60%) of advanced cases occur in the presence or with mixed expression of PTEN (McMenamin et al., 1999) , but with consistently elevated PI3K/Akt signalling. Considering this, other less studied, although potentially important effectors of PIP 3 -mediated signalling including the Akt regulator C-terminal modulator protein (CTMP) (Maira et al., 2001) , Src homology 2-containing inositol phosphatase (SHIP2) (Wisniewski et al., 1999) and PH domain leucine-rich repeat protein phosphatase (PHLPP) (Gao et al., 2005) could be of significance. Prostatic epithelium harbouring low levels of WT PTEN expression may show loss of CTMP, SHIP2 or PHLPP, permitting sufficient PI3K/Akt activation to escape an apoptotic response associated with androgen withdrawal. Although preliminary in suggestion, if this is true, then activation of PIP 3 -negative regulators would, therefore, appear to be a potential therapeutic option. Pharmacological activation of the 5 0 inositol phosphatase function of SHIP2 (Wisniewski et al., 1999) (as opposed to 3 0 phosphatase actions of PTEN) may be a viable option. While the phosphatase function of basal PTEN is constitutive, SHIP2 phosphatase function can be induced dramatically by growth factors and cytokines (Kalesnikoff et al., 2003) , thereby suggesting the possibility of SHIP2 compensation for loss of PTEN function in some Figure 1 Alternative expression of PTEN and GSK3b in progression from androgen-dependent to androgen-independent prostate cancer may facilitate crossregulation of phosphatidylinositol-3-kinase/Akt and Wnt/b-catenin signalling. During AI PrCa, PTEN silencing promotes increased levels of activated Akt and association with phosphatidylinositol-tri-phosphate (PIP 3 ) phospholipids. Enhanced activity of Akt, ILK and Dishevelled (Dvl) promote Ser 9 inactivation of GSK3b, thereby promoting b-catenin and AR gain-of-function. Growth factor stimulation may also crossregulate through PI3K/Akt and Wnt pathways to promote increased cell proliferation (strong interactions ¼ heavy bold; moderate interactions ¼ semibold; weak or not reported ¼ dashed).
AI PrCa epithelium. Pharmacological activation of PHLPP, a recently documented, direct regulator of Akt Ser473 could serve to restore androgen dependency in cancers that have undergone genetic silencing of PTEN. Other therapeutic options may include allosteric activation of PTEN by neutral endopeptidase (Sumitomo et al., 2004) , Magi-2 (Wu et al., 2000) or by PI(4,5)P 2 (i.e. since PI(4), PI(3,4)P 2 and PI(3,5)P 2 phospholipids are not known to activate PTEN) (Campbell et al., 2003) . Thus, while PTEN status is clearly important to the oncogenic fate of prostate epithelium, it is likely that other upstream PI3K/Akt regulators can modulate the ability of PI3K/ Akt to precipitate a proliferative response in a low androgen environment.
Summary and future directions
The balance of prosurvival signalling pathways, the concentration of androgens and stage of PrCa impacts how the androgen/AR signalling axis interacts with the PI3K/Akt axis. It is also clear that decreased PTEN and GSK3b function may elicit increased activity of PI3K/ Akt and AR signalling by way of enhanced autocrine stimulation, transcriptional coactivation or crossregulation with other prosurvival pathways. The pharmacological challenge will be to consider the prosurvival contributions both of PI3K and AR signalling during early-, mid-and late-stage progressive PrCa that allow escape from hormone blockade therapy and resistance to radiation therapy. As such, proteomic studies comparing early-and late-stage prostate samples from the PTENÀ/À mouse model may provide future insight as to which, individual or synergistic, interactions predominate before and after hormone blockade therapy. Determination of which AR post-translational events and coregulators are altered upon PTEN loss and GSK3b alteration may reveal new potential targets for therapeutic intervention. Technically, these changes could be assayed by post-translational (Q-TOF), mass spectrometry (Carter et al., 2004) analysis of AR enrichments. If PTEN mutational silencing and progressive reduction of GSK3b activity are key factors in promoting transcriptional promiscuity of AR, b-catenin/Tcf, AR/ b-catenin or AR/ARE (androgen response element) interactions could all serve as viable therapeutic options in progressive PrCa. However, as b-catenin appears to mediate increases in cell viability by coactivation of AR, rather than Tcf (Chesire et al., 2002; Masiello et al., 2004; , then small molecule targeting of regions necessary for AR/b-catenin interactions (i.e. b-catenin Arm repeats 5-6; AR LBD helices 3, 12) (Yang et al., 2002; Song et al., 2003a) could be promising. Also of note are reports demonstrating that, in PC3 PrCa cells, PTEN not only negates b-catenin function but also promotes substantial induction of E-cadherin (Persad et al., 2001b) . Furthermore, rapamycin inhibition of the downstream PI3K effector, mTOR, also results in induction of E-cadherin in PC3 cells (van der Poel, 2004) . These data imply both an antioncogenic (reduced b-catenin/Tcf interactions) and antimetastatic (increased anchorage dependence) potential for PI3K/Akt inhibition in aggressive PrCa. Increased consideration of how PI3K and AR signalling evolves as a function of expression of critical negative regulators, such as PTEN and GSK3b, will offer new insight as to the identification and timeliness of therapeutic intervention. It may also reveal novel means of how combinatorial therapy may be adjusted for individuals with low-, medium-and high-grade PrCa.
